

Helix BioMedix Announces \$2.9 Million Funding Round

Appoints Lawrence Blake Jones to Board of Directors

Bothell, Washington—March 9, 2010—Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, announced additional funding in the amount of \$2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

“We continue to receive strong support from our investor base in what has been a tough economic climate,” stated R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix, Inc. “The proceeds will be utilized for general corporate purposes, including continued Rx product development and the launch of additional consumer products based on our SmartPeptide™ technology. Helix BioMedix peptides can now be found in a wide range of skin care, blemish control and cosmeceutical products marketed through a variety of channels, including prestige and mass market retailers and catalogues.”

The sale and issuance of convertible promissory notes was in the aggregate principal amount of \$2.9 million and also included warrants to purchase 725,000 shares of the company’s common stock at an exercise price equal to \$0.80 per share. The notes accrue interest at 8 percent per annum and are due and payable on July 1, 2013, unless converted into common stock at an earlier date, as described in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2010.

“We are also pleased to welcome Lawrence Blake Jones to our board of directors,” continued Beatty. “Blake brings to Helix BioMedix extensive experience in law, finance, and business. His complementary skill set and experience add further depth to our board.”

“Helix BioMedix appears to be at an inflection point with respect to its SmartPeptide™ platform,” stated Lawrence Blake Jones. “This is an exciting time to join the company, and I look forward to working with Mr. Beatty, his management team and my fellow board members.”

Jones is currently a managing partner of Scheuermann & Jones, LLC, a Louisiana-based law firm that practices throughout much of the United States. In addition, he serves on various organizations including the board of directors of First NBC Bank where he is a member of the audit committee, the board of directors of First Commerce Holding Company where he is a member of the mergers and acquisitions committee, and the national board of directors for St. Judes Ranch for Children where he is a member of the finance committee. He holds a Juris Doctorate from Tulane Law School and a bachelor’s degree from the Louisiana State University.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking™, SmartPeptide™ and HB-AminoBright™ are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Investor Contact:

Matt Kreps
Shelton Group Investor Relations
(972) 239-5119 X 125
mkreps@sheltongroup.com

Company Contact:

R. Stephen Beatty
President and CEO
(425) 402-8400
sbeatty@helixbiomedix.com